Supergenerics: Esomeprazole Minitablets As A Model | 37458
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

34rd World Congress on Pharmacology

Barcelona, Spain
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Supergenerics: Esomeprazole minitablets as a model

Pharma Middle East

Derar Omari

Yarmouk University, Jordan

ScientificTracks Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X.C1.013

Esomeprazole is the S-isomer of omeprazole. It is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of (H+/K+) ATPase in gastric parietal cell. It is marketed by Astrazeneca Co., under the brand name Nexium® 20 mg and 40 mg as gastro-resistant film coated pellets compressed to tablets (MUPS). Generic products are identical drugs with the brand name drug and are interchangeable with them, and they are therapeutically equivalent. US FDA and other similar authorities do not recognize the term ‘‘Supergenerics’’. These products are also referred as ‘added value generics, new therapeutic entities or hybrids’. These products differ from the original product in formulation or method of delivery. Moreover, these products could be an improved formulation of a known product. A pharmaceutical product developed and manufactured with less excipients and unit operation while maintaining the product therapeutic performance compared to the originator could be considered as an improved therapeutic entity as it reduces the overall cost for manufacturing that could lead to reduced healthcare spending. In this study, enteric coated mini-tablets of ESM were prepared. Bioequivalence studies both under fed and fasting conditions were carried out for the minitablets 40 mg versus Nexium 40 mg MUPS. The results for fasting conditions were within acceptable limits, while fed conditions results were not (higher extent of absorption which means less in vivo degradation than Nexium). The argument of this presentation: Do we accept or reject, particularly when it has no negative effect on the therapeutic efficacy?

Derar Omari has completed his PhD from Cairo University and MSc from Jordan University of Science and Technology. As an Assistant Professor in Faculty of Pharmacy, Yarmouk University, he is teaching Industrial Pharmacy, Pharmaceutics and Physical Pharmacy. He published many papers in reputed journals.

Email: [email protected]